Semaglutide's Safety and Absorption in Patients with Liver Impairment
Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Background
Semaglutide, a potent GLP-1 receptor agonist widely used for Type 2 Diabetes and weight management, is primarily eliminated via metabolic pathways, with renal excretion playing a minor role. However, the impact of hepatic impairment (reduced liver function) on the drug's pharmacokinetics (how the body absorbs, distributes, metabolizes, and excretes a drug) and overall safety profile has not been fully characterized. This study specifically aimed to investigate how varying degrees of liver dysfunction affect semaglutide's exposure in the body and its tolerability.